SWM
TEVA icon

Segment Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Segment Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-24,176
Closed -$876K – 191
2016
Q4 		$876K Buy
+24,176
New +$965K 0.32% 84
2016
Q1 		– Sell
-44,297
Closed -$2.91M – 164
2015
Q4 		$2.91M Sell
44,297
-1,515
-3% -$93.6K 1.1% 31
2015
Q3 		$2.59M Buy
45,812
+3,253
+8% +$211K 0.99% 39
2015
Q2 		$2.52M Sell
42,559
-329
-0.8% -$20.3K 0.87% 42
2015
Q1 		$2.67M Buy
42,888
+5,705
+15% +$332K 0.89% 37
2014
Q4 		$2.14M Buy
37,183
+2,082
+6% +$116K 0.82% 44
2014
Q3 		$1.89M Buy
35,101
+2,372
+7% +$126K 0.72% 51
2014
Q2 		$1.72M Buy
32,729
+2,161
+7% +$110K 0.66% 51
2014
Q1 		$1.61M Buy
30,568
+5,352
+21% +$247K 0.75% 52
2013
Q4 		$1.01M Buy
25,216
+3,474
+16% +$137K 0.5% 64
2013
Q3 		$821K Buy
21,742
+1,263
+6% +$49.3K 0.45% 66
2013
Q2 		$803K Buy
+20,479
New +$798K 0.48% 62

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Segment Wealth Management's TEVA Position: Q1 2017 in Review

Segment Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 24,176 shares — an estimated $876K sold.

Segment Wealth Management first reported a position in TEVA in Q2 2013 and held it in 12 quarters. The position peaked at $2.91M in Q4 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Segment Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Segment Wealth Management sold 24,176 Teva Pharmaceuticals shares in Q1 2017, an estimated $876K.
  • Segment Wealth Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Segment Wealth Management's Teva Pharmaceuticals position peaked at $2.91M in Q4 2015.
  • 686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Segment Wealth Management's 13F filing for Q1 2017, filed 8 May 2017.